In-ho K. Kim

St. Vincent's Hospital
Suwon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 98 publications

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Journal: Oncoimmunology

Published: June 29, 2026

EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 01, 2026

Agreement, Compliance, and Practice Change of the Korean Practice Guidelines for Gastric Cancer 2022: A Nationwide Multidisciplinary Survey.

Agreement, Compliance, and Practice Change of the Korean Practice Guidelines for Gastric Cancer 2022: A Nationwide Multidisciplinary Survey.

Journal: Journal of gastric cancer

Published: February 24, 2026

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Journal: Nature communications

Published: February 06, 2026

Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications.

Clinical and Molecular Characteristics of KRAS Codon-Specific Mutations in Advanced Pancreatic Ductal Adenocarcinoma with Prognostic and Therapeutic Implications.

Journal: International journal of molecular sciences

Published: September 15, 2025

Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW.

Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW.

Journal: Cancer research and treatment

Published: August 28, 2025

Dynamic Integrative Immune Profiling Reveals Early Biomarkers of Response and Prognosis in Advanced Gastric Cancer Treated with Nivolumab Plus Chemotherapy.

Dynamic Integrative Immune Profiling Reveals Early Biomarkers of Response and Prognosis in Advanced Gastric Cancer Treated with Nivolumab Plus Chemotherapy.

Journal: Cancers

Published: August 16, 2025

Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13).

Real World Efficacy of 1st-Line Nivolumab Plus Ipilimumab and its Practical Predictive Biomarkers in Advanced Renal Cell Carcinoma: First Analysis from RENOIR Study (KCSG GU22-13).

Journal: Cancer research and treatment

Published: August 08, 2025

Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation.

Prognostic role of effective radiation dose to immune cells in esophageal cancer treated with definitive chemoradiation.

Journal: PloS one

Published: June 22, 2025

Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin.

Liposomal irinotecan with fluorouracil and leucovorin as salvage treatment for advanced biliary tract cancer refractory to gemcitabine and cisplatin.

Journal: Frontiers in oncology

Published: June 18, 2025

Patients' Preferences for Gastric Cancer Treatment: A Cross-Sectional Study on Decision-Making in Multidisciplinary Treatment Strategies.

Patients' Preferences for Gastric Cancer Treatment: A Cross-Sectional Study on Decision-Making in Multidisciplinary Treatment Strategies.

Journal: Journal of gastric cancer

Published: March 24, 2025

Real-World Comparison of Trifluridine-Tipiracil with or Without Bevacizumab in Patients with Refractory Metastatic Colorectal Cancer.

Real-World Comparison of Trifluridine-Tipiracil with or Without Bevacizumab in Patients with Refractory Metastatic Colorectal Cancer.

Journal: Biomedicines

Published: March 22, 2025

Showing 1-12 of 98

Last Updated: 09/26/2026